Stay updated on Patisiran for hATTR Amyloidosis Clinical Trial

Sign up to get notified when there's something new on the Patisiran for hATTR Amyloidosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Patisiran for hATTR Amyloidosis Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The page now displays the expanded-access study record for patisiran in hereditary transthyretin-mediated amyloidosis, including study details, eligibility criteria, intervention, sponsor, and record dates.
    Difference
    30%
    Check dated 2026-11-09T13:08:45.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The footer revision number changes from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-11-02T12:29:37.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A site-wide banner announces the NIH transition from using “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-26T12:37:09.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision number changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-19T13:27:33.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-12T14:26:35.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Access to the study record is blocked by a 403 Forbidden page, with the error document structure added (doctype, metadata, title). A minimal header/footer remains, and many related links and terms have been removed from the page.
    Difference
    14%
    Check dated 2026-09-28T19:04:59.000Z thumbnail image

Stay in the know with updates to Patisiran for hATTR Amyloidosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Patisiran for hATTR Amyloidosis Clinical Trial page.